Russell Investments Group Ltd. Has $1.94 Million Holdings in GRAIL, Inc. $GRAL

Russell Investments Group Ltd. boosted its position in shares of GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 255.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,403 shares of the company's stock after buying an additional 20,416 shares during the period. Russell Investments Group Ltd. owned approximately 0.07% of GRAIL worth $1,939,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of GRAL. Bank of America Corp DE boosted its position in shares of GRAIL by 29.0% during the 1st quarter. Bank of America Corp DE now owns 914,114 shares of the company's stock worth $47,241,000 after acquiring an additional 205,611 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in GRAIL by 154,361.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 91,132 shares of the company's stock valued at $7,531,000 after acquiring an additional 91,073 shares during the last quarter. Vanguard Group Inc. raised its position in GRAIL by 9.0% during the fourth quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company's stock valued at $169,535,000 after purchasing an additional 163,790 shares in the last quarter. WIM INVESTMENT MANAGEMENT Ltd raised its position in GRAIL by 68.9% during the fourth quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 106,400 shares of the company's stock valued at $9,107,000 after purchasing an additional 43,400 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in GRAIL by 1,036.8% during the fourth quarter. Pictet Asset Management Holding SA now owns 40,926 shares of the company's stock worth $3,585,000 after purchasing an additional 37,326 shares during the last quarter.

Insider Activity at GRAIL

In related news, insider Andrew John Partridge sold 1,491 shares of the firm's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the sale, the insider owned 163,738 shares of the company's stock, valued at $10,001,117.04. This trade represents a 0.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.83% of the company's stock.

GRAIL Price Performance

Shares of NASDAQ:GRAL opened at $67.87 on Friday. The company has a market cap of $3.03 billion, a price-to-earnings ratio of -6.96 and a beta of 3.24. The firm has a 50 day simple moving average of $67.58 and a 200 day simple moving average of $65.35. GRAIL, Inc. has a one year low of $29.95 and a one year high of $118.84.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating analysts' consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. As a group, analysts expect that GRAIL, Inc. will post -10.41 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GRAL. Mizuho raised their target price on GRAIL from $58.00 to $65.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of GRAIL in a report on Friday, July 17th. The Goldman Sachs Group assumed coverage on GRAIL in a research report on Friday, June 5th. They set a "neutral" rating and a $60.00 price objective for the company. Wolfe Research began coverage on GRAIL in a research note on Tuesday, June 2nd. They issued a "peer perform" rating on the stock. Finally, TD Cowen reiterated a "buy" rating on shares of GRAIL in a research report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $67.78.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source